SRPT : Analysis & Opinions

  1. Sarepta Drug Gets UnitedHealth Coverage (SRPT, UNH)

    December 2, 2016
    At long last! Sarepta's muscular dystrophy drug Exondys 51 finally got coverage by UnitedHealth insurance.
  2. Sarepta Tumbles After Anthem’s Refusal (SRPT, ANTM)

    October 10, 2016
    Sarepta’s recent bull run came to a halt when share prices declined by more than 9% following refusal by a leading U.S. insurer ...
  3. Summit Wins Genetic Disease Drug Label (SMMT, SRPT)

    October 7, 2016
    Summit makes steady progress in developing its treatment for Duchenne muscular dystrophy.
  4. Sarepta’s Exondys 51 Drug May Cost $300,000 (SRPT)

    October 5, 2016
    Following FDA approval, industry speculation is running high about the possible price of Sarepta's muscular dystrophy Exondys ...
  5. Sarepta Inks Key DMD Deal (SRPT)

    October 4, 2016
    Sarepta continues to be on a deal-making spree following FDA approval for its DMD drug and expects to benefit from Summit's ...
  6. Sarepta’s Partnership Spikes Catabasis (SRPT)

    October 1, 2016
    Sarepta is exploring all possible options to expedite development for its recently approved Exondys 51 drug.
  7. Sarepta’s Secret Weapon: Priority Review Voucher

    September 28, 2016
    Uncertainty about the extension of pediatric priority review voucher (PRV) program will allow Sarepta to benefit significantly ...
  8. Sarepta’s Manufacturing Challenge (SRPT)

    September 27, 2016
    Amid doubts about scalability of manufacturing, Sarepta has laid out plans to serve the high unmet demand for the approved ...
  9. BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT)

    September 26, 2016
    Following its loss in a U.S. patent infringement ruling, BioMarin is taking further steps agains rival Sarepta
  10. Sarpeta Approval Challenged by FDA (SRPT)

    September 23, 2016
    Will Sarepta’s approval be revoked following the FDA commissioner’s call for retraction of the company's 2013 study?
  11. Sarpeta Raises Offering After FDA Approval (SRPT)

    September 23, 2016
    Sarepta has increased the amount of capital to be raised to $300 million in a public offering
  12. Sarepta Announces Offering of Common Stock (SRPT)

    September 22, 2016
    Sarepta Therapeutics announces a $225 million capital-raising public offering.
  13. Sarepta Wins Favorable USPTO Decisions (SRPT)

    September 21, 2016
    Sarepta records another success with a positive decision from the U.S. Patent and Trademark Office.
  14. Sarepta's New Drug May Make It a Takeover (SRPT)

    September 21, 2016
    Following the FDA approval for its muscular dystrophy drug, eteplirsen, Sarepta may be high on target list for an acquisition ...
  15. FDA Approval Leads 75% Rise in Sarepta (SRPT)

    September 20, 2016
    Stock prices soared 75% following the news of Sarepta Therapeutics winning a much-awaited approval for its DMD therapy.
  16. Sarepta's Drug Is Stuck in the FDA Quagmire (SRPT)

    September 16, 2016
    Sarepta’s stock surge is fading as its muscular dystrophy drug faces uncertain FDA approval
  17. The Market In 5 Minutes: We're Gathered Here To Get Through This ...

    June 7, 2016
    Below is a tool used by the Benzinga News Desk each trading day -- it's a look at everything happening in the market, in ...
  18. Biotech Stocks: Are They Back?

    June 1, 2016
    The bearish trends over the past year have started to reverse themselves which has benefted the biotech industry
  19. Sarepta Therapeutics One Step Closer to Drug Approval

    July 3, 2015
    Analysts are optimistic about the future of Sarepta as the biotechnology company submits a New Drug Application the FDA.
  20. Sarepta Gets FDA Green Light to Submit Application (SRPT, BMRN)

    May 20, 2015
    It's not often you see a biotech soar more than 60% after announcing plans to submit a marketing application to the Food ...
  21. Sarepta Earnings Preview: 3 Things to Watch For (SRPT)

    May 4, 2015
    Since the stock peaked at more than $55 per share in October 2013, Sarepta Therapeutics' (NASDAQ: SRPT) shareholders have ...
  22. Sarepta Therapeutics' 3 Biggest Risks (SRPT)

    March 23, 2015
    There are arguably few diagnoses as frightening for children and their parents as Duchenne muscular dystrophy, or DMD. Based ...
Trading Center